Urogen Pharma was classified in the Zacks Medical - Biomedical and Genetics industry and outperformed the S&P 500 stock gain this year.
1 report, 1 independent
Updated Aug 7
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Urogen Pharma was classified in the Zacks Medical - Biomedical and Genetics industry and outperformed the S&P 500 stock gain this year.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
Coverage
Newest first; wire copies grouped- ZacksUrogen Pharma (URGN) Reports Q2 Loss, Lags Revenue Estimates Urogen Pharma (URGN) came out with a quarterly loss of $1.05 per share versus the Zacks Consensus Estimate of a loss of $0.82. This compar